Jacqueline K. Hewitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacqueline K. Hewitt has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Garry L. Warne
3 shared publications- Andrew H. Sinclair
Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC 3052, Australia
2 shared publications Campbell Paul
Royal Children's Hospital, Melbourne, Vic
2 shared publications- Erin Turbitt
University of Technology Sydney, Ultimo, Australia
2 shared publications Garry L Warne
Royal Children's Hospital, Melbourne, Vic
2 shared publicationsLouise K Newman
Centre for Developmental Psychiatry and Psychology, Monash University, Melbourne, VIC
2 shared publications
Latest Publications
- 10 December 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (9) , 1516-1518
Close monitoring is required in the neonate affected by maternal Graves disease due to the potential for both central hypothyroidism and primary hyperthyroidism
- 10 December 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (9) , 1516-1518
Close monitoring is required in the neonate affected by maternal Graves disease due to the potential for both central hypothyroidism and primary hyperthyroidism
- 1 June 2015
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (3) , 437-447
Hormone replacement in disorders of sex development: Current thinking
- 1 June 2015
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (3) , 437-447
Hormone replacement in disorders of sex development: Current thinking
- Open Access
- 8 April 2014
- Published by BMJ in Journal of Medical Genetics
- Vol. 51 (6) , 375-387
Comprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum
Background: NKX2-1 encodes a transcription factor with large impact on the development of brain, lung and thyroid. Germline mutations of NKX2-1 can lead to dysfunction and malformations of these organs. Starting from the largest coherent collection of patients with a suspected phenotype to date, we systematically evaluated frequency, quality and spectrum of phenotypic consequences of NKX2-1 mutations. Methods: After identifying mutations by Sanger sequencing and array CGH, we comprehensively reanalysed the phenotype of affected patients and their relatives. We employed electrophoretic mobility shift assay (EMSA) to detect alterations of NKX2-1 DNA binding. Gene expression was monitored by means of in situ hybridisation and compared with the expression level of MBIP, a candidate gene presumably involved in the disorders and closely located in close genomic proximity to NKX2-1. Results: Within 101 index patients, we detected 17 point mutations and 10 deletions. Neurological symptoms were the most consistent finding (100%), followed by lung affection (78%) and thyroidal dysfunction (75%). Novel symptoms associated with NKX2-1 mutations comprise abnormal height, bouts of fever and cardiac septum defects. In contrast to previous reports, our data suggest that missense mutations in the homeodomain of NKX2-1 not necessarily modify its DNA binding capacity and that this specific type of mutations may be associated with mild pulmonary phenotypes such as asthma. Two deletions did not include NKX2-1, but MBIP, whose expression spatially and temporarily coincides with NKX2-1 in early murine development. Conclusions: The high incidence of NKX2-1 mutations strongly recommends the routine screen for mutations in patients with corresponding symptoms. However, this analysis should not be confined to the exonic sequence alone, but should take advantage of affordable NGS technology to expand the target to adjacent regulatory sequences and the NKX2-1 interactome in order to maximise the yield of this diagnostic effort.
- 8 April 2014
- Published by BMJ in Journal of Medical Genetics
- Vol. 51 (6) , 375-387
Open AccessComprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum
Background: NKX2-1 encodes a transcription factor with large impact on the development of brain, lung and thyroid. Germline mutations of NKX2-1 can lead to dysfunction and malformations of these organs. Starting from the largest coherent collection of patients with a suspected phenotype to date, we systematically evaluated frequency, quality and spectrum of phenotypic consequences of NKX2-1 mutations. Methods: After identifying mutations by Sanger sequencing and array CGH, we comprehensively reanalysed the phenotype of affected patients and their relatives. We employed electrophoretic mobility shift assay (EMSA) to detect alterations of NKX2-1 DNA binding. Gene expression was monitored by means of in situ hybridisation and compared with the expression level of MBIP, a candidate gene presumably involved in the disorders and closely located in close genomic proximity to NKX2-1. Results: Within 101 index patients, we detected 17 point mutations and 10 deletions. Neurological symptoms were the most consistent finding (100%), followed by lung affection (78%) and thyroidal dysfunction (75%). Novel symptoms associated with NKX2-1 mutations comprise abnormal height, bouts of fever and cardiac septum defects. In contrast to previous reports, our data suggest that missense mutations in the homeodomain of NKX2-1 not necessarily modify its DNA binding capacity and that this specific type of mutations may be associated with mild pulmonary phenotypes such as asthma. Two deletions did not include NKX2-1, but MBIP, whose expression spatially and temporarily coincides with NKX2-1 in early murine development. Conclusions: The high incidence of NKX2-1 mutations strongly recommends the routine screen for mutations in patients with corresponding symptoms. However, this analysis should not be confined to the exonic sequence alone, but should take advantage of affordable NGS technology to expand the target to adjacent regulatory sequences and the NKX2-1 interactome in order to maximise the yield of this diagnostic effort.
- 5 November 2012
- Published by AMPCo in Medical Journal of Australia
- Vol. 197 (9) , 490
Adverse effects of adult topical androgen use on children
- 5 November 2012
- Published by AMPCo in Medical Journal of Australia
- Vol. 197 (9) , 490
Adverse effects of adult topical androgen use on children
- 3 September 2012
- Published by AMPCo in Medical Journal of Australia
- Vol. 197 (5) , 274
Hormone treatment of gender identity disorder in a cohort of children and adolescents
- 3 September 2012
- Published by AMPCo in Medical Journal of Australia
- Vol. 197 (5) , 274
Hormone treatment of gender identity disorder in a cohort of children and adolescents
- 21 May 2012
- Published by AMPCo in Medical Journal of Australia
- Vol. 196 (9) , 578-581
Hormone treatment of gender identity disorder in a cohort of children and adolescents
To describe the experience of hormone treatment of gender identity disorder (GID) in children and adolescents within a specialist clinic. Design, patients and setting: Cohort study by medical record review of children aged 0–17 years referred during 2003–2011 for management at the GID clinic in a tertiary paediatric referral centre — the Royal ...
- 21 May 2012
- Published by AMPCo in Medical Journal of Australia
- Vol. 196 (9) , 578-581
Hormone treatment of gender identity disorder in a cohort of children and adolescents
To describe the experience of hormone treatment of gender identity disorder (GID) in children and adolescents within a specialist clinic. Design, patients and setting: Cohort study by medical record review of children aged 0–17 years referred during 2003–2011 for management at the GID clinic in a tertiary paediatric referral centre — the Royal ...
- 9 November 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (3) , 348-351
A multi-exon deletion within WWOX is associated with a 46,XY disorder of sex development
Disorders of sex development (DSD) are congenital conditions where chromosomal, gonad or genital development is atypical. In a significant proportion of 46,XY DSD cases it is not possible to identify a causative mutation, making genetic counseling difficult and potentially hindering optimal treatment. Here, we describe the analysis of a 46,XY DSD patient that presented at birth with ambiguous genitalia. Histological analysis of the surgically removed gonads showed bilateral undifferentiated gonadal tissue and immature testis, both containing malignant germ cells. We screened genomic DNA from this patient for deletions and duplications using an Illumina whole-genome SNP microarray. This analysis revealed a heterozygous deletion within the WWOX gene on chromosome 16, removing exons 6–8. Analysis of parental DNA showed that the deletion was inherited from the mother. cDNA analysis confirmed that the deletion maintained the reading frame, with exon 5 being spliced directly onto exon 9. This deletion is the first description of a germline rearrangement affecting the coding sequence of WWOX in humans. Previously described Wwox knockout mouse models showed gonadal abnormalities, supporting a role for WWOX in human gonad development.
- 9 November 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (3) , 348-351
A multi-exon deletion within WWOX is associated with a 46,XY disorder of sex development
Disorders of sex development (DSD) are congenital conditions where chromosomal, gonad or genital development is atypical. In a significant proportion of 46,XY DSD cases it is not possible to identify a causative mutation, making genetic counseling difficult and potentially hindering optimal treatment. Here, we describe the analysis of a 46,XY DSD patient that presented at birth with ambiguous genitalia. Histological analysis of the surgically removed gonads showed bilateral undifferentiated gonadal tissue and immature testis, both containing malignant germ cells. We screened genomic DNA from this patient for deletions and duplications using an Illumina whole-genome SNP microarray. This analysis revealed a heterozygous deletion within the WWOX gene on chromosome 16, removing exons 6–8. Analysis of parental DNA showed that the deletion was inherited from the mother. cDNA analysis confirmed that the deletion maintained the reading frame, with exon 5 being spliced directly onto exon 9. This deletion is the first description of a germline rearrangement affecting the coding sequence of WWOX in humans. Previously described Wwox knockout mouse models showed gonadal abnormalities, supporting a role for WWOX in human gonad development.
- 1 November 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (31) , 4137-4142
Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to SDHB Mutations
Purpose: To present data on the high rate of SDHB mutations in patients with metastatic pheochromocytoma/paraganglioma whose initial tumor presentation began in childhood or adolescence. Patients and Methods: From 2000 to 2010, 263 patients with pheochromocytoma/paraganglioma were evaluated through the National Institutes of Health (NIH), Bethesda, MD. Of the 263 patients, 125 patients were found to have metastatic disease; of these 125 patients, 32 patients presented with a tumor before 20 years of age. An additional 17 patients presented with a tumor before 20 years of age but demonstrated no development of metastatic disease. Genetic testing for mutations in the VHL, MEN, and SDHB/C/D genes was performed on patients without previously identified genetic mutations. Results: Of the 32 patients who presented with metastatic disease and had their primary tumor in childhood or adolescence, sequence analysis of germline DNA showed SDHB mutations in 23 patients (71.9%), SDHD mutations in three patients (9.4%), VHL mutations in two patients (6.3%), and an absence of a known mutation in four patients (12.5%). The majority of these 32 patients (78.1%) presented with primary tumors in an extra-adrenal location. Conclusion: The majority of patients with metastatic pheochromocytoma/paraganglioma who presented with a primary tumor in childhood/adolescence had primary extra-adrenal tumors and harbored SDHB mutations. Except for primary tumors located in the head and neck where SDHD genetic testing is advised, we recommend that patients who present with metastatic pheochromocytoma/paraganglioma with primary tumor development in childhood or adolescence undergo SDHB genetic testing before they undergo testing for other gene mutations, unless clinical presentation or family history suggests a different mutation.
- 1 November 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (31) , 4137-4142
Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to SDHB Mutations
Purpose: To present data on the high rate of SDHB mutations in patients with metastatic pheochromocytoma/paraganglioma whose initial tumor presentation began in childhood or adolescence. Patients and Methods: From 2000 to 2010, 263 patients with pheochromocytoma/paraganglioma were evaluated through the National Institutes of Health (NIH), Bethesda, MD. Of the 263 patients, 125 patients were found to have metastatic disease; of these 125 patients, 32 patients presented with a tumor before 20 years of age. An additional 17 patients presented with a tumor before 20 years of age but demonstrated no development of metastatic disease. Genetic testing for mutations in the VHL, MEN, and SDHB/C/D genes was performed on patients without previously identified genetic mutations. Results: Of the 32 patients who presented with metastatic disease and had their primary tumor in childhood or adolescence, sequence analysis of germline DNA showed SDHB mutations in 23 patients (71.9%), SDHD mutations in three patients (9.4%), VHL mutations in two patients (6.3%), and an absence of a known mutation in four patients (12.5%). The majority of these 32 patients (78.1%) presented with primary tumors in an extra-adrenal location. Conclusion: The majority of patients with metastatic pheochromocytoma/paraganglioma who presented with a primary tumor in childhood/adolescence had primary extra-adrenal tumors and harbored SDHB mutations. Except for primary tumors located in the head and neck where SDHD genetic testing is advised, we recommend that patients who present with metastatic pheochromocytoma/paraganglioma with primary tumor development in childhood or adolescence undergo SDHB genetic testing before they undergo testing for other gene mutations, unless clinical presentation or family history suggests a different mutation.
- 1 July 2011
- Published by Oxford University Press (OUP)
- p. 1014-1023
Sex determination and differentiation
A baby’s sex––one of its primary identifying features—is usually decided on the basis of a very brief inspection of the external genitalia completed by the birth attendant in the space of a few seconds. If there is a penis, the baby is declared to be a boy. If, instead, there is no penis and the genital folds are separated by a cleft, it is a girl. Recognizing the difference between male and female is easy when appearances are absolutely typical. Once in every 4500 births, however, it is impossible to say whether the baby is a boy or a girl because the genitalia are quite atypical or, in other words, ambiguous (1). In other cases, the external genitalia appear male or female, but the child is subsequently discovered, perhaps in the course of investigating or treating an inguinal hernia, to have internal anatomy normally associated with the opposite sex. For example, a female (with complete androgen insensitivity) can be born with testes and a male (with persistent Müllerian duct syndrome) can be born with fallopian tubes and a uterus. Other children are born with incompletely differentiated gonads that are neither typical testes nor ovaries; and may even contain elements of both, termed ovotestes. Chromosomes are no certain guide to sex either, as one in every 250 people has a major variation in the number of sex chromosomes (2). It is also possible to be chimeric, for example, 46,XX/46,XY.
- 1 July 2011
- Published by Oxford University Press (OUP)
- p. 1014-1023
Sex determination and differentiation
A baby’s sex––one of its primary identifying features—is usually decided on the basis of a very brief inspection of the external genitalia completed by the birth attendant in the space of a few seconds. If there is a penis, the baby is declared to be a boy. If, instead, there is no penis and the genital folds are separated by a cleft, it is a girl. Recognizing the difference between male and female is easy when appearances are absolutely typical. Once in every 4500 births, however, it is impossible to say whether the baby is a boy or a girl because the genitalia are quite atypical or, in other words, ambiguous (1). In other cases, the external genitalia appear male or female, but the child is subsequently discovered, perhaps in the course of investigating or treating an inguinal hernia, to have internal anatomy normally associated with the opposite sex. For example, a female (with complete androgen insensitivity) can be born with testes and a male (with persistent Müllerian duct syndrome) can be born with fallopian tubes and a uterus. Other children are born with incompletely differentiated gonads that are neither typical testes nor ovaries; and may even contain elements of both, termed ovotestes. Chromosomes are no certain guide to sex either, as one in every 250 people has a major variation in the number of sex chromosomes (2). It is also possible to be chimeric, for example, 46,XX/46,XY.